Evaluate https://www.evaluate.com/ Pharma commercial intelligence, news & analysis Fri, 20 Mar 2026 12:48:43 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 https://www.evaluate.com/wp-content/uploads/2023/09/favicon.svg Evaluate https://www.evaluate.com/ 32 32 246032434 Three Things we Learned in our 2026 Orphan Drugs Webinar https://www.evaluate.com/blog/blog-three-things-we-learned-orphan-drugs-2026/ https://www.evaluate.com/blog/blog-three-things-we-learned-orphan-drugs-2026/#respond Fri, 20 Mar 2026 12:48:43 +0000 https://www.evaluate.com/?p=49728 Orphan drugs are forecast to make up 21% of all prescription drug sales by 2032, according to Evaluate forecasts. So it’s hardly surprising that we had a lot of interest in our latest orphan drugs market webinar. If you missed it, you can find the on-demand version here. If you’re saving that treat for later, […]

The post Three Things we Learned in our 2026 Orphan Drugs Webinar appeared first on Evaluate.

]]> https://www.evaluate.com/blog/blog-three-things-we-learned-orphan-drugs-2026/feed/ 0 49728 Orphan Drugs at a Crossroads: Bigger Numbers, Tougher Calls https://www.evaluate.com/blog/orphan-drugs-at-a-crossroads/ https://www.evaluate.com/blog/orphan-drugs-at-a-crossroads/#respond Thu, 12 Mar 2026 10:49:04 +0000 https://www.evaluate.com/?p=49230 Drugs for rare diseases have played an increasingly significant role in the biopharma market for years. I’ve been working on Evaluate’s annual orphan drugs report for the past five years and it’s clear from looking at the evolution of the data in that time that orphans offer considerable opportunity. We’ve just published this year’s report, […]

The post Orphan Drugs at a Crossroads: Bigger Numbers, Tougher Calls appeared first on Evaluate.

]]> https://www.evaluate.com/blog/orphan-drugs-at-a-crossroads/feed/ 0 49230 Three Things we Learned in our 2026 Preview Webinar https://www.evaluate.com/blog/three-things-we-learned-in-our-2026-preview-webinar/ https://www.evaluate.com/blog/three-things-we-learned-in-our-2026-preview-webinar/#respond Fri, 23 Jan 2026 11:39:45 +0000 https://www.evaluate.com/?p=46231 Obesity. China. FDA turmoil. Our pharma 2026 Preview webinar was not the place to look for a change in the big pharma buzzwords for this year. These big themes remain with us for now. But there was still plenty for our expert panel to discuss during the session. If you missed it, you can catch […]

The post Three Things we Learned in our 2026 Preview Webinar appeared first on Evaluate.

]]> https://www.evaluate.com/blog/three-things-we-learned-in-our-2026-preview-webinar/feed/ 0 46231 A Clearer View from JPM 2026 – Day Four https://www.evaluate.com/blog/a-clearer-view-from-jpm-2026-day-four/ https://www.evaluate.com/blog/a-clearer-view-from-jpm-2026-day-four/#respond Fri, 16 Jan 2026 15:12:56 +0000 https://www.evaluate.com/?p=45995 The final day of JPM 2026 didn’t bring any late-breaking megadeals or big surprise announcements but there was plenty to keep biotech watchers engaged to the end. Our Biomedtracker team has summarized all the presentations in their Day Four report which you can download here, and below are a few highlights to ponder. Large cap […]

The post A Clearer View from JPM 2026 – Day Four appeared first on Evaluate.

]]> https://www.evaluate.com/blog/a-clearer-view-from-jpm-2026-day-four/feed/ 0 45995 A Clearer View from JPM 2026 – Day Three https://www.evaluate.com/blog/a-clearer-view-from-jpm-2026-day-3/ https://www.evaluate.com/blog/a-clearer-view-from-jpm-2026-day-3/#respond Thu, 15 Jan 2026 15:31:32 +0000 https://www.evaluate.com/?p=45930 Day Three of JPM 2026 continued with a sense of both positivity and stability – both noticeably lacking in recent years. Here are a few of the highlights from the Biomedtracker team and you can catch up with all the action from Day Three in our full report which is available here. Mega cap momentum […]

The post A Clearer View from JPM 2026 – Day Three appeared first on Evaluate.

]]> https://www.evaluate.com/blog/a-clearer-view-from-jpm-2026-day-3/feed/ 0 45930 A Clearer View from JPM 2026 – Day Two https://www.evaluate.com/blog/a-clearer-view-from-jpm-2026-day-two/ https://www.evaluate.com/blog/a-clearer-view-from-jpm-2026-day-two/#respond Wed, 14 Jan 2026 13:56:03 +0000 https://www.evaluate.com/?p=45897 Day Two at JPM carried a similar message from Day One: focus where you can win, deploy capital with discipline, and back assets with real clinical traction. Our Biomedtracker team has captured every detail in the full report which is available here, but here are some highlights. Mega caps sharpen their growth engines AstraZeneca’s session […]

The post A Clearer View from JPM 2026 – Day Two appeared first on Evaluate.

]]> https://www.evaluate.com/blog/a-clearer-view-from-jpm-2026-day-two/feed/ 0 45897 A Clearer View from JPM 2026 – Day One https://www.evaluate.com/blog/a-clearer-view-from-jpm-2026-day-one/ https://www.evaluate.com/blog/a-clearer-view-from-jpm-2026-day-one/#respond Tue, 13 Jan 2026 17:52:35 +0000 https://www.evaluate.com/?p=45830 Here we are again. January means the JP Morgan Healthcare Conference and all eyes in the pharma and biotech space turn to San Francisco. Our Biomedtracker team is providing daily reports to bring you the highlights of each day’s activities. There’s loads to digest in the full Day One report, so here are a few […]

The post A Clearer View from JPM 2026 – Day One appeared first on Evaluate.

]]> https://www.evaluate.com/blog/a-clearer-view-from-jpm-2026-day-one/feed/ 0 45830 How Biotechs Can Win Capital in 2026: Highlights from Evaluate’s Financing Forum https://www.evaluate.com/blog/how-biotechs-can-win-capital-in-2026-highlights-from-evaluates-financing-forum/ https://www.evaluate.com/blog/how-biotechs-can-win-capital-in-2026-highlights-from-evaluates-financing-forum/#respond Thu, 08 Jan 2026 14:24:30 +0000 https://www.evaluate.com/?p=45668 January may be upon us but allow me one chance to look back at one of December’s highlights; Evaluate’s event that took place in London. Evaluate Financing Forum: Biotech Strategies for Accessing Capital saw more than 50 professionals from pharma, biotech and financing come together for a morning of networking and knowledge sharing about biotech […]

The post How Biotechs Can Win Capital in 2026: Highlights from Evaluate’s Financing Forum appeared first on Evaluate.

]]> https://www.evaluate.com/blog/how-biotechs-can-win-capital-in-2026-highlights-from-evaluates-financing-forum/feed/ 0 45668 Three Things we Learned in our Unlocking Innovation in Pharma Webinar https://www.evaluate.com/blog/three-things-we-learned-in-our-unlocking-innovation-in-pharma-webinar/ https://www.evaluate.com/blog/three-things-we-learned-in-our-unlocking-innovation-in-pharma-webinar/#respond Fri, 21 Nov 2025 15:14:49 +0000 https://www.evaluate.com/?p=44344 There is life beyond ADCs and GLP-1s. Given the level of attention these particular areas have received in recent years, it can be hard to remember that – but it was a key message from our recent webinar, “Unlocking Innovation: What pharma deals reveal about tomorrow’s therapies”. Our business development and licensing experts investigated where […]

The post Three Things we Learned in our Unlocking Innovation in Pharma Webinar appeared first on Evaluate.

]]> https://www.evaluate.com/blog/three-things-we-learned-in-our-unlocking-innovation-in-pharma-webinar/feed/ 0 44344 What Does Dealmaking Tell Us About the Therapies of Tomorrow? https://www.evaluate.com/blog/what-does-dealmaking-tell-us-about-the-therapies-of-tomorrow/ https://www.evaluate.com/blog/what-does-dealmaking-tell-us-about-the-therapies-of-tomorrow/#respond Wed, 12 Nov 2025 13:48:56 +0000 https://www.evaluate.com/?p=43576 Our upcoming Unlocking Innovation webinar analyzes dealmaking activity to identify mechanisms and technologies that have been trending in recent years, beyond ADCs or GLP-1s. While these two modalities have dominated headlines and investor interest, thanks to their blockbuster potential in oncology and metabolic disease, there’s a broader wave of innovation that could shape the future […]

The post What Does Dealmaking Tell Us About the Therapies of Tomorrow? appeared first on Evaluate.

]]> https://www.evaluate.com/blog/what-does-dealmaking-tell-us-about-the-therapies-of-tomorrow/feed/ 0 43576 It’s Time to Act: Why Trump is good for European Biopharma… https://www.evaluate.com/blog/its-time-to-act-on-european-biopharma/ https://www.evaluate.com/blog/its-time-to-act-on-european-biopharma/#respond Mon, 10 Nov 2025 13:49:38 +0000 https://www.evaluate.com/?p=43324 Call it a kick up the backside. For decades, Europe has failed to address its biopharma weaknesses – too little lab-to-drug translation, too little scale-up capital, non-existent public markets and penny-pinching drug budgets. Then came President Trump. Love him or hate him, his call-out of the US-EU drug pricing gap, his tariff-talk and his efforts […]

The post It’s Time to Act: Why Trump is good for European Biopharma… appeared first on Evaluate.

]]> https://www.evaluate.com/blog/its-time-to-act-on-european-biopharma/feed/ 0 43324 Ready for a Cliffhanger? Register for our Loss of Exclusivity Webinar https://www.evaluate.com/blog/loss-of-exclusivity-webinar/ https://www.evaluate.com/blog/loss-of-exclusivity-webinar/#respond Tue, 07 Oct 2025 10:39:40 +0000 https://www.evaluate.com/?p=41137 For the past few years, our annual World Preview report has included analysis of the potential scale of the 2025-2030 pharma patent cliff. It’s one of the features that garners the most questions from readers, particularly around how a potential loss of $300bn can sit alongside forecast growth of over 7% in the same time […]

The post Ready for a Cliffhanger? Register for our Loss of Exclusivity Webinar appeared first on Evaluate.

]]> https://www.evaluate.com/blog/loss-of-exclusivity-webinar/feed/ 0 41137 Three Things We Learned in our Corporate-Level Competitive Intelligence Webinar https://www.evaluate.com/blog/three-things-we-learned-in-our-corporate-level-competitive-intelligence-webinar/ https://www.evaluate.com/blog/three-things-we-learned-in-our-corporate-level-competitive-intelligence-webinar/#respond Fri, 03 Oct 2025 14:20:06 +0000 https://www.evaluate.com/?p=41120 Our Competitive Intelligence consulting team has been busy recently. Fresh from presenting at Pharma CI, Kelly Chamberlain led our latest webinar, “Mind the Gap: Supporting Cross-Functional Teams with Corporate Level CI”. She was joined by Paul D’Souza and Amanda Micklus and Paul is straight off to Pharma Cimicon in Berlin to share his wisdom with […]

The post Three Things We Learned in our Corporate-Level Competitive Intelligence Webinar appeared first on Evaluate.

]]> https://www.evaluate.com/blog/three-things-we-learned-in-our-corporate-level-competitive-intelligence-webinar/feed/ 0 41120 Enterprise-Level Peer Analysis: Solving a Gap in Competitive Intelligence https://www.evaluate.com/blog/enterprise-level-peer-analysis-solving-a-gap-in-competitive-intelligence/ https://www.evaluate.com/blog/enterprise-level-peer-analysis-solving-a-gap-in-competitive-intelligence/#respond Mon, 29 Sep 2025 17:16:50 +0000 https://www.evaluate.com/?p=40617 Recently, I was delighted to attend the Pharma CI event in Newark, NJ which brought together competitive intelligence (CI) leaders from across the pharmaceutical industry to tackle the key challenges that face CI teams every day. In addition to catching up with familiar faces and meeting new people, I had the pleasure of taking the […]

The post Enterprise-Level Peer Analysis: Solving a Gap in Competitive Intelligence appeared first on Evaluate.

]]> https://www.evaluate.com/blog/enterprise-level-peer-analysis-solving-a-gap-in-competitive-intelligence/feed/ 0 40617 How Can Analogs Help Pharma Companies Forecast Effectively? https://www.evaluate.com/video-blog/how-can-analogs-help-pharma-companies-forecast-effectively/ https://www.evaluate.com/video-blog/how-can-analogs-help-pharma-companies-forecast-effectively/#respond Thu, 18 Sep 2025 09:11:29 +0000 https://www.evaluate.com/?p=40104 When you’re bringing a new drug to market, one of the many forecasting challenges is the ability to root your forecasts in reality. This is where analogs come in. Analogs are a really powerful forecasting tool and by selecting a suite of analogs can enable forecasters to take the past and use it as a […]

The post How Can Analogs Help Pharma Companies Forecast Effectively? appeared first on Evaluate.

]]> https://www.evaluate.com/video-blog/how-can-analogs-help-pharma-companies-forecast-effectively/feed/ 0 40104 When Every Decision Counts: Equipping Pharma Sales Teams for Market Success https://www.evaluate.com/blog/when-every-decision-counts-equipping-pharma-sales-teams-for-market-success/ https://www.evaluate.com/blog/when-every-decision-counts-equipping-pharma-sales-teams-for-market-success/#respond Mon, 11 Aug 2025 18:02:32 +0000 https://www.evaluate.com/?p=38654 Therapies entering new therapeutic spaces bring unique challenges; not only to pharmaceutical companies, but to the HCPs entrusted with their use and the patients whose outcomes depend on them. In markets with limited precedent, every clinical decision carries financial, emotional, and procedural weight. Healthcare professionals need clarity on treatment value across different patient volumes, transparent […]

The post When Every Decision Counts: Equipping Pharma Sales Teams for Market Success appeared first on Evaluate.

]]> https://www.evaluate.com/blog/when-every-decision-counts-equipping-pharma-sales-teams-for-market-success/feed/ 0 38654 What’s the role of Excel in a Forecaster’s Software Toolkit? https://www.evaluate.com/video-blog/forecasters-software-toolkit/ https://www.evaluate.com/video-blog/forecasters-software-toolkit/#respond Thu, 07 Aug 2025 15:17:02 +0000 https://www.evaluate.com/?p=38703 There are many challenges that biopharma forecasters face but perhaps one of the greatest is asking people to change their behavior. No matter how many fancy forecasting tools and solutions you may have, people know what they like and one thing they like is Excel. In this video, I talk about why there is still […]

The post What’s the role of Excel in a Forecaster’s Software Toolkit? appeared first on Evaluate.

]]> https://www.evaluate.com/video-blog/forecasters-software-toolkit/feed/ 0 38703 Strategic Deals and Investment Moves Influencing the GLP-1 Marketplace https://www.evaluate.com/blog/strategic-deals-and-investment-moves-influencing-glp-1-marketplace-deal-making/ https://www.evaluate.com/blog/strategic-deals-and-investment-moves-influencing-glp-1-marketplace-deal-making/#respond Thu, 31 Jul 2025 11:28:02 +0000 https://www.evaluate.com/?p=38489 While the rapid growth of the GLP-1 and obesity market presents enormous financial opportunities for life sciences companies, it also carries legal, regulatory, and reimbursement risks. With that in mind, Norstella were recently invited to present a session at the American Conference Institute Inaugural Summit on GLP-1 Law & Policy, Using deals data from Evaluate […]

The post Strategic Deals and Investment Moves Influencing the GLP-1 Marketplace appeared first on Evaluate.

]]> https://www.evaluate.com/blog/strategic-deals-and-investment-moves-influencing-glp-1-marketplace-deal-making/feed/ 0 38489 Back from BIO: The Evolving Biotech Investment Landscape https://www.evaluate.com/blog/the-evolving-biotech-landscape/ https://www.evaluate.com/blog/the-evolving-biotech-landscape/#respond Fri, 11 Jul 2025 10:06:48 +0000 https://www.evaluate.com/?p=37867 “Nuclear winter” and “extinction event” were two of the less-than-positive terms used during last month’s BIO International convention to describe the state of play for biotechs in recent years. Fortunately, while this may be only a partial exaggeration, there were many more positive notes as well. Fresh from my third BIO International and after digesting […]

The post Back from BIO: The Evolving Biotech Investment Landscape appeared first on Evaluate.

]]> https://www.evaluate.com/blog/the-evolving-biotech-landscape/feed/ 0 37867 Three Things we Learned in our World Preview 2025 Webinar https://www.evaluate.com/blog/three-things-we-learned-in-our-world-preview-webinar/ https://www.evaluate.com/blog/three-things-we-learned-in-our-world-preview-webinar/#respond Thu, 03 Jul 2025 11:49:09 +0000 https://www.evaluate.com/?p=37697 Every year, I am hugely fortunate to work with our team of experts to create the Evaluate World Preview report. Now in its 18th year, the World Preview offers a data-rich look at the future of the pharmaceutical industry. It’s full of forecast data that help to paint a picture of the shifting sands of […]

The post Three Things we Learned in our World Preview 2025 Webinar appeared first on Evaluate.

]]> https://www.evaluate.com/blog/three-things-we-learned-in-our-world-preview-webinar/feed/ 0 37697 How can Pharma Navigate Turbulent Seas? Find out in our World Preview Webinar https://www.evaluate.com/blog/world-preview-webinar/ https://www.evaluate.com/blog/world-preview-webinar/#respond Fri, 27 Jun 2025 11:04:05 +0000 https://www.evaluate.com/?p=37268 The Evaluate World Preview report is a staple of the pharma calendar. The 2025 edition has just been published, marking the 18th year of providing forecast and trend insights to decision makers across the industry. If you’re not familiar with the World Preview, I recommend taking a look. Not only does it provide a wealth […]

The post How can Pharma Navigate Turbulent Seas? Find out in our World Preview Webinar appeared first on Evaluate.

]]> https://www.evaluate.com/blog/world-preview-webinar/feed/ 0 37268 Inside the Fundamentals of Forecasting: Highlights from Our Boston Workshop https://www.evaluate.com/blog/forecasting-training-workshop-highlights/ https://www.evaluate.com/blog/forecasting-training-workshop-highlights/#respond Wed, 21 May 2025 14:27:11 +0000 https://www.evaluate.com/?p=34575 Recently, the J+D Forecasting team welcomed a diverse group of professionals to Boston for our two-day Fundamentals of Forecasting multi-client workshop, run in collaboration with Evaluate. From emerging clinical-stage biotechs to global Top 10 pharma companies, delegates gathered to deepen their knowledge, share experiences, and engage in peer-to-peer learning in a relaxed, collaborative environment. The […]

The post Inside the Fundamentals of Forecasting: Highlights from Our Boston Workshop appeared first on Evaluate.

]]> https://www.evaluate.com/blog/forecasting-training-workshop-highlights/feed/ 0 34575 Master patient flow analysis to predict pharma demand and provide better patient access. https://www.evaluate.com/blog/master-patient-flow-analysis-to-predict-pharma-demand/ https://www.evaluate.com/blog/master-patient-flow-analysis-to-predict-pharma-demand/#respond Mon, 19 May 2025 14:11:29 +0000 https://www.evaluate.com/?p=33457 Inaccurate patient flow analysis can create severe consequences even for the most diligent pharmaceutical companies. Risks include vastly overestimating or underestimating the value or opportunity for a particular product which may ultimately impact on patients’ ability to access potentially life-saving treatments. So, how can pharma companies minimize these risks and actively deliver products which support […]

The post Master patient flow analysis to predict pharma demand and provide better patient access. appeared first on Evaluate.

]]> https://www.evaluate.com/blog/master-patient-flow-analysis-to-predict-pharma-demand/feed/ 0 33457 Three Things we Learned in our Biotech Commercialization Webinar https://www.evaluate.com/blog/biotech-commercialization-webinar-insights/ https://www.evaluate.com/blog/biotech-commercialization-webinar-insights/#respond Fri, 16 May 2025 11:32:32 +0000 https://www.evaluate.com/?p=33990 The board at Verona Pharma was taking the steps necessary to take its chronic obstructive pulmonary disorder (COPD) drug to market years ahead of its launch in 2024. This long term view was one of the details shared by Verona’s Chief Commercial Officer, Chris Martin during our recent webinar “Going Solo: What’s Driving the Biotech […]

The post Three Things we Learned in our Biotech Commercialization Webinar appeared first on Evaluate.

]]> https://www.evaluate.com/blog/biotech-commercialization-webinar-insights/feed/ 0 33990 A Blueprint for Biotech Commercialization? https://www.evaluate.com/blog/biotech-commercialization/ https://www.evaluate.com/blog/biotech-commercialization/#respond Mon, 12 May 2025 13:09:43 +0000 https://www.evaluate.com/?p=33060 “Think twice, and twice more, before launching your own drug. It is unimaginably difficult and complex”. Those were the words of a biotech CEO I interviewed more than a decade ago. The advice remains sound. Yet today there are tailwinds encouraging more biotechs to take their prized assets all the way to market. (And let’s […]

The post A Blueprint for Biotech Commercialization? appeared first on Evaluate.

]]> https://www.evaluate.com/blog/biotech-commercialization/feed/ 0 33060 Choosing the most Appropriate Time Series Algorithm for Accurate Pharmaceutical Sales Forecasts https://www.evaluate.com/blog/time-series-algorithm-for-accurate-pharma-forecasts/ https://www.evaluate.com/blog/time-series-algorithm-for-accurate-pharma-forecasts/#respond Fri, 09 May 2025 13:01:49 +0000 https://www.evaluate.com/?p=32929 When it comes to forecasting sales in the pharmaceutical industry, several time series algorithms are commonly used to analyze historical data and project trends into the future. These can be classified into three main types: Automated Smoothing First is the automated smoothing algorithm. This includes techniques such as growth rates and linear regression. Smoothing algorithms […]

The post Choosing the most Appropriate Time Series Algorithm for Accurate Pharmaceutical Sales Forecasts appeared first on Evaluate.

]]> https://www.evaluate.com/blog/time-series-algorithm-for-accurate-pharma-forecasts/feed/ 0 32929 Three Things we Learned in our “First to Market Myth” Webinar https://www.evaluate.com/blog/three-things-we-learned-in-our-first-to-market-myth-webinar/ https://www.evaluate.com/blog/three-things-we-learned-in-our-first-to-market-myth-webinar/#respond Fri, 02 May 2025 13:12:30 +0000 https://www.evaluate.com/?p=32585 It is a truth universally acknowledged that a new market in possession of unmet need will reward its first entrant with commercial advantage. Except, that “truth” may be somewhat overstated. This was the topic of our recent webinar, “The First to Market Myth: What Really Drives Launch Success?”. During the session, Evaluate consultants Mark Lansdell, […]

The post Three Things we Learned in our “First to Market Myth” Webinar appeared first on Evaluate.

]]> https://www.evaluate.com/blog/three-things-we-learned-in-our-first-to-market-myth-webinar/feed/ 0 32585 Should Pharma Companies Really Race to be First to Market? https://www.evaluate.com/blog/should-pharma-companies-really-race-to-be-first-in-market/ https://www.evaluate.com/blog/should-pharma-companies-really-race-to-be-first-in-market/#respond Wed, 23 Apr 2025 15:02:13 +0000 https://www.evaluate.com/?p=31928 For Portfolio Strategy teams in pharma companies, there is a constant juggling act to ensure that the right therapies are being prioritized for the right indications. This requires a clear understanding of the potential market size, payer perspectives and competitive environment. With the right data and insight, you can plan your go-to-market approach – and […]

The post Should Pharma Companies Really Race to be First to Market? appeared first on Evaluate.

]]> https://www.evaluate.com/blog/should-pharma-companies-really-race-to-be-first-in-market/feed/ 0 31928 Three Things we Learned in our Mastering Long-Range Planning Processes Webinar https://www.evaluate.com/blog/mastering-long-range-planning-processes-webinar/ https://www.evaluate.com/blog/mastering-long-range-planning-processes-webinar/#respond Wed, 16 Apr 2025 16:35:00 +0000 https://www.evaluate.com/?p=31404 Our webinar on Long-Range Planning (LRP) forecasting took place recently and – as always – our experts Andrew Ward and Amanda Randall were on fine form. Full disclosure – this was our second webinar on this topic. You can catch up with part one – The Forecaster’s Guide to Long Range Planning here. The session […]

The post Three Things we Learned in our Mastering Long-Range Planning Processes Webinar appeared first on Evaluate.

]]> https://www.evaluate.com/blog/mastering-long-range-planning-processes-webinar/feed/ 0 31404 The High-Stakes Landscape for Competitive Intelligence https://www.evaluate.com/blog/the-high-stakes-landscape-for-competitive-intelligence/ https://www.evaluate.com/blog/the-high-stakes-landscape-for-competitive-intelligence/#respond Tue, 15 Apr 2025 12:36:29 +0000 https://www.evaluate.com/?p=31375 Competitive Intelligence teams occupy quite a unique place in a biopharma organization. They collaborate with a really wide range of stakeholders – sales, regulatory, forecasting and many more. This gives CI professionals insight into countless strategic initiatives across the company. But it also means trying to support a lot of different, sometimes almost contradictory needs. […]

The post The High-Stakes Landscape for Competitive Intelligence appeared first on Evaluate.

]]> https://www.evaluate.com/blog/the-high-stakes-landscape-for-competitive-intelligence/feed/ 0 31375 What makes a good (and bad) pharmaceutical forecast model https://www.evaluate.com/blog/what-makes-a-good-and-bad-pharmaceutical-forecast-model/ https://www.evaluate.com/blog/what-makes-a-good-and-bad-pharmaceutical-forecast-model/#respond Thu, 10 Apr 2025 08:01:45 +0000 https://www.evaluate.com/?p=30557 Having good forecast models is critical for effective and efficient decision-making. This will deliver accurate and reliable insights to help support business objectives and drive brand or company growth, highlight risk, and quantify opportunity. This article explores the key ingredients needed for developing good pharmaceutical forecast models. It’s widely accepted that there is no such […]

The post What makes a good (and bad) pharmaceutical forecast model appeared first on Evaluate.

]]> https://www.evaluate.com/blog/what-makes-a-good-and-bad-pharmaceutical-forecast-model/feed/ 0 30557 Mastering Long-Range Planning: From Challenges to Actionable Solutions https://www.evaluate.com/blog/mastering-long-range-planning-from-challenges-to-actionable-solutions/ https://www.evaluate.com/blog/mastering-long-range-planning-from-challenges-to-actionable-solutions/#respond Wed, 02 Apr 2025 15:33:05 +0000 https://www.evaluate.com/?p=29978 Are you in the midst of yet another challenging Long Range Planning (LRP) cycle and wondering if there is a better way? If the answer is yes, may I suggest you register for our upcoming webinar. In our first webinar on this topic, we talked about some of the biggest challenges in LRP. In this […]

The post Mastering Long-Range Planning: From Challenges to Actionable Solutions appeared first on Evaluate.

]]> https://www.evaluate.com/blog/mastering-long-range-planning-from-challenges-to-actionable-solutions/feed/ 0 29978 How can you Improve Efficiencies in your Long-Range Planning? https://www.evaluate.com/blog/how-can-you-improve-efficiencies-in-your-long-range-planning/ https://www.evaluate.com/blog/how-can-you-improve-efficiencies-in-your-long-range-planning/#respond Tue, 25 Mar 2025 14:18:23 +0000 https://www.evaluate.com/?p=29416 No element of pharmaceutical forecasting is easy but there’s a particular challenge in long-range planning. The range of components involved results in a greater degree of complexity which can allow inaccuracies to creep in very easily. We covered some of the key challenges in a recent webinar, The Forecaster’s Guide to Long-Range Planning, which you […]

The post How can you Improve Efficiencies in your Long-Range Planning? appeared first on Evaluate.

]]> https://www.evaluate.com/blog/how-can-you-improve-efficiencies-in-your-long-range-planning/feed/ 0 29416 Three Things We Learned in Our Orphan Drugs Webinar https://www.evaluate.com/blog/orphan-drugs-webinar/ https://www.evaluate.com/blog/orphan-drugs-webinar/#respond Fri, 14 Mar 2025 17:28:47 +0000 https://www.evaluate.com/?p=28095 Our recent orphan drugs webinar provided a wealth of insights into the current state and future of the orphan drug market. It was based on our annual report (which is available here) and if you missed it, I recommend taking the time to watch the on-demand version. Our panel included the report’s author, Melanie Senior […]

The post Three Things We Learned in Our Orphan Drugs Webinar appeared first on Evaluate.

]]> https://www.evaluate.com/blog/orphan-drugs-webinar/feed/ 0 28095 The Pharma Files: What Have you Missed? https://www.evaluate.com/blog/insight-about-the-pharma-market/ https://www.evaluate.com/blog/insight-about-the-pharma-market/#respond Thu, 13 Mar 2025 09:46:03 +0000 https://www.evaluate.com/?p=21764 As you probably know, Evaluate has an incredibly rich and comprehensive set of data and insight about the pharma market. This means we’re able to produce some really valuable reports, webinars and articles that provide insight around the most exciting areas of the industry. And we create rather a lot of them, which can make […]

The post The Pharma Files: What Have you Missed? appeared first on Evaluate.

]]> https://www.evaluate.com/blog/insight-about-the-pharma-market/feed/ 0 21764 Is it Time to Rethink Orphan Drugs? https://www.evaluate.com/blog/is-it-time-to-rethink-orphan-drugs/ https://www.evaluate.com/blog/is-it-time-to-rethink-orphan-drugs/#respond Mon, 03 Mar 2025 09:51:26 +0000 https://www.evaluate.com/?p=21339 If you follow Evaluate’s regular white papers and blogs, you may be familiar with our annual report that investigates the state of the orphan drug market. I’ve been involved in analyzing that data for the past three years, and have just finished the process for this year’s report which will be published soon. One of […]

The post Is it Time to Rethink Orphan Drugs? appeared first on Evaluate.

]]> https://www.evaluate.com/blog/is-it-time-to-rethink-orphan-drugs/feed/ 0 21339 How Pharma Professionals Rate Our Forecasting Training https://www.evaluate.com/blog/how-pharma-professionals-rate-our-forecasting-training/ https://www.evaluate.com/blog/how-pharma-professionals-rate-our-forecasting-training/#respond Tue, 25 Feb 2025 16:04:37 +0000 https://www.evaluate.com/?p=28094 Formal training is essential for stakeholder teams looking to enhance their forecasting expertise. By deepening their understanding of fundamental principles, methodologies, and process steps, teams can approach forecasting with greater confidence and ensure they are applying best practices effectively. However, learning should not be a passive process. We believe self-assessment is a powerful tool for […]

The post How Pharma Professionals Rate Our Forecasting Training appeared first on Evaluate.

]]> https://www.evaluate.com/blog/how-pharma-professionals-rate-our-forecasting-training/feed/ 0 28094 Three Things we Learned in our Long-Range Planning Webinar https://www.evaluate.com/blog/three-things-we-learned-in-our-long-range-planning-webinar/ https://www.evaluate.com/blog/three-things-we-learned-in-our-long-range-planning-webinar/#respond Mon, 17 Feb 2025 14:38:04 +0000 https://www.evaluate.com/?p=23063 How’s your long-range planning going? If you’re tasked with the forecasting processes for a pharma or biotech company, you may be in the midst of this annual cycle at the moment. Long-range planning (or LRP as the cool forecasters call it) provides a really important guide to company performance over five to 10 years. Like […]

The post Three Things we Learned in our Long-Range Planning Webinar appeared first on Evaluate.

]]> https://www.evaluate.com/blog/three-things-we-learned-in-our-long-range-planning-webinar/feed/ 0 23063 Overcoming Challenges in Long-Range Planning Forecasting https://www.evaluate.com/blog/overcoming-challenges-in-long-range-planning-forecasting/ https://www.evaluate.com/blog/overcoming-challenges-in-long-range-planning-forecasting/#respond Thu, 30 Jan 2025 16:22:20 +0000 https://www.evaluate.com/?p=21859 Long-Range Planning (LRP) is no easy feat. As someone who has worked extensively in this area, I’ve seen firsthand the complexities and challenges that professionals face – whether it’s managing diverse portfolios, navigating cross-functional dynamics, or working with tools that just don’t fit the bill. That’s why I’m thrilled to be taking part in this […]

The post Overcoming Challenges in Long-Range Planning Forecasting appeared first on Evaluate.

]]> https://www.evaluate.com/blog/overcoming-challenges-in-long-range-planning-forecasting/feed/ 0 21859 Three Things we Learned in our 2025 Preview Webinar https://www.evaluate.com/blog/2025-preview-webinar/ https://www.evaluate.com/blog/2025-preview-webinar/#respond Fri, 24 Jan 2025 14:04:43 +0000 https://www.evaluate.com/?p=23059 The first Evaluate webinar of the year is in the bag. Based on our 2025 Preview report, this session brought together three of our industry experts to discuss what the year ahead might hold for pharma. They may not have had a crystal ball, but they had plenty of detailed data and insight which is […]

The post Three Things we Learned in our 2025 Preview Webinar appeared first on Evaluate.

]]> https://www.evaluate.com/blog/2025-preview-webinar/feed/ 0 23059 What Will 2025 Hold for Pharma? https://www.evaluate.com/blog/what-will-2025-hold-for-pharma/ https://www.evaluate.com/blog/what-will-2025-hold-for-pharma/#respond Thu, 16 Jan 2025 14:21:33 +0000 https://www.evaluate.com/?p=23054 Once again, the pharma industry starts a new year with hopes of a recovery. Will 2025 finally see a return of IPOs? Of mega-mergers? Of huge rounds of investment? Perhaps, but more likely this year will simply be a few steps in the right direction. There is still a great deal of uncertainty, particularly around […]

The post What Will 2025 Hold for Pharma? appeared first on Evaluate.

]]> https://www.evaluate.com/blog/what-will-2025-hold-for-pharma/feed/ 0 23054 Meet the Evaluate Team: Magda Lis-Podjaska https://www.evaluate.com/blog/meet-the-evaluate-team-magda-lis-podjaska/ https://www.evaluate.com/blog/meet-the-evaluate-team-magda-lis-podjaska/#respond Tue, 07 Jan 2025 09:31:59 +0000 https://www.evaluate.com/?p=18019 Listening to our customers is a big focus for Evaluate. To ensure our solutions are continually evolving to meet market challenges, we find all sorts of ways to understand what our clients want from us. And coordinating all that activity is the delightful Magda Lis-Podjaska, our Global Voice of the Customer Lead. She took time […]

The post Meet the Evaluate Team: Magda Lis-Podjaska appeared first on Evaluate.

]]> https://www.evaluate.com/blog/meet-the-evaluate-team-magda-lis-podjaska/feed/ 0 18019 Biopharma Reading List: The Evaluate Top 10 of 2024 https://www.evaluate.com/blog/biopharma-reading-list-the-evaluate-top-10-of-2024/ https://www.evaluate.com/blog/biopharma-reading-list-the-evaluate-top-10-of-2024/#respond Tue, 10 Dec 2024 11:42:14 +0000 https://www.evaluate.com/?p=17240 Obesity. The Inflation Reduction Act. Orphan Drugs. CDMOs. Successful forecasting techniques. We’ve covered all this and more in our biopharma reports, webinars and analysis throughout 2024. As I’ve had the pleasure of working with our experts to create all this content, I thought year-end was a splendid opportunity to share the most-read pieces of the […]

The post Biopharma Reading List: The Evaluate Top 10 of 2024 appeared first on Evaluate.

]]> https://www.evaluate.com/blog/biopharma-reading-list-the-evaluate-top-10-of-2024/feed/ 0 17240 Epidemiology forecasting and the impact of data sources on accuracy https://www.evaluate.com/blog/epidemiology-forecasting-the-impact-of-data-sources/ https://www.evaluate.com/blog/epidemiology-forecasting-the-impact-of-data-sources/#respond Mon, 25 Nov 2024 10:27:02 +0000 https://www.evaluate.com/?p=15928 The relationship between epidemiology forecasting and data sources is a complex one. Generating accurate forecasts relies heavily on data, and factors such as real-world data and artificial intelligence (AI) have an increasing impact.   Factors affecting forecast quality and accuracy There are a few factors that contribute to the accuracy of epidemiological forecasts. Firstly, the […]

The post Epidemiology forecasting and the impact of data sources on accuracy appeared first on Evaluate.

]]> https://www.evaluate.com/blog/epidemiology-forecasting-the-impact-of-data-sources/feed/ 0 15928 Three Things we Learned in our Launch Excellence Webinar https://www.evaluate.com/blog/three-things-we-learned-in-our-launch-excellence-webinar/ https://www.evaluate.com/blog/three-things-we-learned-in-our-launch-excellence-webinar/#respond Fri, 22 Nov 2024 14:00:24 +0000 https://www.evaluate.com/?p=16676 Picture the scene. You’ve got a new, hugely promising new drug in the pipeline and all the clinical signs are looking good. Which means you have to start focusing on your launch strategy to ensure commercial success. You need to refine your list of potential opportunities and threats, and develop forecasts that will ensure the […]

The post Three Things we Learned in our Launch Excellence Webinar appeared first on Evaluate.

]]> https://www.evaluate.com/blog/three-things-we-learned-in-our-launch-excellence-webinar/feed/ 0 16676 Three Things we Learned in our “Taking the Pharma Industry Pulse” Webinar https://www.evaluate.com/blog/three-things-we-learned-in-our-pharma-industry-pulse-webinar/ https://www.evaluate.com/blog/three-things-we-learned-in-our-pharma-industry-pulse-webinar/#respond Tue, 19 Nov 2024 17:32:05 +0000 https://www.evaluate.com/?p=16595 One of the great things about working in the pharma industry is the opportunity to listen to very clever people talking about fascinating topics and the latest trends in the market. Events like BIO-Europe are brilliant for this, and there is always plenty to unpack after the panels, keynotes and fireside chats have ended. Our […]

The post Three Things we Learned in our “Taking the Pharma Industry Pulse” Webinar appeared first on Evaluate.

]]> https://www.evaluate.com/blog/three-things-we-learned-in-our-pharma-industry-pulse-webinar/feed/ 0 16595 CDMOs: A Paradigm Change for Pharma? https://www.evaluate.com/blog/cdmo-buzzword-or-paradigm-change/ https://www.evaluate.com/blog/cdmo-buzzword-or-paradigm-change/#respond Mon, 18 Nov 2024 11:35:16 +0000 https://www.evaluate.com/?p=16527 At the recent CPHI exhibition in a very wet Milan, you couldn’t move for booths expounding on the capabilities of the world’s manufacturing, services, packaging and ingredients players. Some of these companies formerly considered themselves to be Contract Research Organisations (CROs) or CMOs (Contract Manufacturing Organisations) but now proudly display the letters CDMO (Contract Development […]

The post CDMOs: A Paradigm Change for Pharma? appeared first on Evaluate.

]]> https://www.evaluate.com/blog/cdmo-buzzword-or-paradigm-change/feed/ 0 16527 Analogue forecasting: the power of the past to predict the future https://www.evaluate.com/blog/analogue-forecasting-to-predict-the-future/ https://www.evaluate.com/blog/analogue-forecasting-to-predict-the-future/#respond Wed, 13 Nov 2024 15:23:47 +0000 https://www.evaluate.com/?p=16444 Launching a first-in-class drug is high on the wish list of most pharma companies, but achieving that goal is not without its challenges. While patient demand for innovative therapies will always be high, modelling their impact on the treatment landscape is an uncertain business and the stakes are too high to rely on little more […]

The post Analogue forecasting: the power of the past to predict the future appeared first on Evaluate.

]]> https://www.evaluate.com/blog/analogue-forecasting-to-predict-the-future/feed/ 0 16444 Meet the Evaluate Team: Penny Wills https://www.evaluate.com/blog/meet-the-evaluate-team-penny-wills/ https://www.evaluate.com/blog/meet-the-evaluate-team-penny-wills/#respond Wed, 13 Nov 2024 12:08:38 +0000 https://www.evaluate.com/?p=16440 Penny Wills joined the Evaluate team through its acquisition of J+D Forecasting at the start of 2024. As a seasoned forecasting implementation expert, Penny’s role encompasses working closely with clients to understand their requirements for their forecasting models and ensuring successful delivery by working with stakeholders across the team. I grabbed some time with Penny […]

The post Meet the Evaluate Team: Penny Wills appeared first on Evaluate.

]]> https://www.evaluate.com/blog/meet-the-evaluate-team-penny-wills/feed/ 0 16440 Join the Discussion: Dealmaking, Innovation and Geopolitics in Pharma https://www.evaluate.com/blog/join-the-discussion-dealmaking-innovation-and-geopolitics-in-pharma/ https://www.evaluate.com/blog/join-the-discussion-dealmaking-innovation-and-geopolitics-in-pharma/#respond Tue, 12 Nov 2024 12:51:48 +0000 https://www.evaluate.com/?p=16409 BIO-Europe took place last week in Stockholm. It’s one of the last big biopharma events of the year and a great time to take stock of where the industry stands as the new year approaches. I was at the convention, taking part in a fireside chat to discuss global innovation trends. Also featuring on the […]

The post Join the Discussion: Dealmaking, Innovation and Geopolitics in Pharma appeared first on Evaluate.

]]> https://www.evaluate.com/blog/join-the-discussion-dealmaking-innovation-and-geopolitics-in-pharma/feed/ 0 16409 Mastering the Move from Phase III to Launch https://www.evaluate.com/blog/from-trials-to-take-off-the-road-to-launch-excellence/ https://www.evaluate.com/blog/from-trials-to-take-off-the-road-to-launch-excellence/#respond Wed, 06 Nov 2024 13:48:04 +0000 https://www.evaluate.com/?p=16206 The journey from Phase III clinical trials to a successful product launch is both exciting and challenging. It’s a crucial stage that sets the foundation for how a new product will perform in the market. But with resources often already allocated to established brands, and the need for precise forecasting and planning, launching a new […]

The post Mastering the Move from Phase III to Launch appeared first on Evaluate.

]]> https://www.evaluate.com/blog/from-trials-to-take-off-the-road-to-launch-excellence/feed/ 0 16206 Meet the Evaluate Team: Andy Mills https://www.evaluate.com/blog/meet-the-team-andy-mills/ https://www.evaluate.com/blog/meet-the-team-andy-mills/#respond Wed, 30 Oct 2024 14:54:19 +0000 https://www.evaluate.com/?p=16006 If you work with Evaluate, you’ll probably be familiar with our delightful Customer Success team. They’re the people who help ensure that our customers can use our solutions to navigate the pharma landscape, and answer their key questions to help them make the right decisions about their business. One member of this team is Andy […]

The post Meet the Evaluate Team: Andy Mills appeared first on Evaluate.

]]> https://www.evaluate.com/blog/meet-the-team-andy-mills/feed/ 0 16006 Out-Licencing Strategies: How to Secure the Right Partner https://www.evaluate.com/blog/out-licencing-strategies-how-to-secure-the-right-partner/ https://www.evaluate.com/blog/out-licencing-strategies-how-to-secure-the-right-partner/#respond Wed, 16 Oct 2024 12:25:26 +0000 https://www.evaluate.com/?p=15003 When a biotech or biopharma’s flagship asset is ready for out-licensing, which strategies will get it noticed by the right partners? To gain the attention of larger players, companies need to present clear evidence of their asset’s efficacy and market potential, along with a realistic understanding of the types of deals they can secure. Leveraging […]

The post Out-Licencing Strategies: How to Secure the Right Partner appeared first on Evaluate.

]]> https://www.evaluate.com/blog/out-licencing-strategies-how-to-secure-the-right-partner/feed/ 0 15003 Five Steps to Refining Your In-Licencing Strategy https://www.evaluate.com/blog/5-steps-to-refining-your-in-licencing-strategy/ https://www.evaluate.com/blog/5-steps-to-refining-your-in-licencing-strategy/#respond Tue, 15 Oct 2024 10:44:37 +0000 https://www.evaluate.com/?p=14981 For pharma companies, biotech assets present significant opportunities to strengthen pipelines with reduced risk. However, with such a vast ecosystem, identifying the right assets that align with your strategy can be a challenge. Whether the dealmaking goal is a quick win in a major market or securing an innovative product early, finding the most valuable […]

The post Five Steps to Refining Your In-Licencing Strategy appeared first on Evaluate.

]]> https://www.evaluate.com/blog/5-steps-to-refining-your-in-licencing-strategy/feed/ 0 14981 Enhancing Competitive Intelligence in Biopharma: Key Strategies and Insights https://www.evaluate.com/blog/enhancing-competitive-intelligence-in-biopharma/ https://www.evaluate.com/blog/enhancing-competitive-intelligence-in-biopharma/#respond Mon, 14 Oct 2024 16:51:11 +0000 https://www.evaluate.com/?p=14957 In the ever-evolving landscape of biopharma and biotech, competitive intelligence (CI) plays a crucial role in driving strategic decisions and maintaining a competitive edge. At the recent Pharma CI conference in Newark, I had the pleasure of presenting to an audience of CI leaders to discuss ways of optimising the strategic value of cross-functional CI. […]

The post Enhancing Competitive Intelligence in Biopharma: Key Strategies and Insights appeared first on Evaluate.

]]> https://www.evaluate.com/blog/enhancing-competitive-intelligence-in-biopharma/feed/ 0 14957 In Case You Missed It: Three Things we Learned in our Dealmaking Trends Webinar https://www.evaluate.com/blog/3-things-we-learned-about-dealmaking-trends/ https://www.evaluate.com/blog/3-things-we-learned-about-dealmaking-trends/#respond Wed, 02 Oct 2024 10:04:07 +0000 https://www.evaluate.com/?p=14169 If there’s one thing that the experts at Evaluate love, it’s rummaging around in data to identify trends in the pharma market. One area that is always fascinating to explore is dealmaking trends – and that’s just what my colleagues Ben Folwell and Duncan Sweeney did during our recent webinar, “Licence Drivers: Trends in Pharma […]

The post In Case You Missed It: Three Things we Learned in our Dealmaking Trends Webinar appeared first on Evaluate.

]]> https://www.evaluate.com/blog/3-things-we-learned-about-dealmaking-trends/feed/ 0 14169 2024 Dealmaking: What’s the Score? https://www.evaluate.com/blog/2024-dealmaking-whats-the-score/ https://www.evaluate.com/blog/2024-dealmaking-whats-the-score/#respond Fri, 27 Sep 2024 14:51:14 +0000 https://www.evaluate.com/?p=14007 Volume is up but value is down. That’s the headline of the dealmaking scene for the first half of 2024. There’s not been a mega-merger in the vein of 2023’s Pfizer/Seagen deal, though the Novo/Catalent deal aimed at boosting supplies of the semaglutide products Ozempic and Wegovy is certainly notable. Even so, the 18% increase […]

The post 2024 Dealmaking: What’s the Score? appeared first on Evaluate.

]]> https://www.evaluate.com/blog/2024-dealmaking-whats-the-score/feed/ 0 14007 Meet the Team: Kelly Chamberlain https://www.evaluate.com/blog/meet-the-evaluate-team-kelly-chamberlain/ https://www.evaluate.com/blog/meet-the-evaluate-team-kelly-chamberlain/#respond Thu, 08 Aug 2024 15:21:27 +0000 https://www.evaluate.com/?p=12082 Kelly Chamberlain may not have been at the company very long, but that didn’t stop me swooping in to find out a little more about her. Kelly has joined Norstella, Evaluate’s parent company as Partner, Market Intelligence. She’s an expert in supporting competitive intelligence workflows and ensuring that CI teams can maximise the strategic value […]

The post Meet the Team: Kelly Chamberlain appeared first on Evaluate.

]]> https://www.evaluate.com/blog/meet-the-evaluate-team-kelly-chamberlain/feed/ 0 12082 In Case You Missed It: Three Things we Learned in our AI Forecasting Webinar https://www.evaluate.com/blog/in-case-you-missed-it-three-things-we-learned-in-our-ai-forecasting-webinar/ https://www.evaluate.com/blog/in-case-you-missed-it-three-things-we-learned-in-our-ai-forecasting-webinar/#respond Tue, 06 Aug 2024 16:01:15 +0000 https://www.evaluate.com/?p=12016 If you missed our recent webinar, AI and ML in Pharma: Redefining the Forecasting Landscape, then I hope it’s because you were on a lovely vacation somewhere. Now that you’re back, though, you’ll be delighted to know that it’s available on demand so you can catch up at your leisure. Our panel, which included Daniel […]

The post In Case You Missed It: Three Things we Learned in our AI Forecasting Webinar appeared first on Evaluate.

]]> https://www.evaluate.com/blog/in-case-you-missed-it-three-things-we-learned-in-our-ai-forecasting-webinar/feed/ 0 12016 Unlocking the Power of AI in Pharmaceutical Forecasting https://www.evaluate.com/blog/unlocking-the-power-of-ai-in-pharmaceutical-forecasting/ https://www.evaluate.com/blog/unlocking-the-power-of-ai-in-pharmaceutical-forecasting/#respond Wed, 24 Jul 2024 12:14:26 +0000 https://www.evaluate.com/?p=11527 There is no shortage of discussion about the opportunities presented by artificial intelligence and AI in the pharma industry. 50% of global healthcare companies plan to implement AI strategies by next year and AI’s impact on new drug development is expected to grow 40% annually. There is no part of the pharmaceutical ecosystem that isn’t […]

The post Unlocking the Power of AI in Pharmaceutical Forecasting appeared first on Evaluate.

]]> https://www.evaluate.com/blog/unlocking-the-power-of-ai-in-pharmaceutical-forecasting/feed/ 0 11527 In Case You Missed It: Three Things we Learned in our World Preview Webinar https://www.evaluate.com/blog/3-things-we-learned-world-preview-webinar/ https://www.evaluate.com/blog/3-things-we-learned-world-preview-webinar/#respond Thu, 18 Jul 2024 16:16:45 +0000 https://www.evaluate.com/?p=11443 Evaluate’s annual World Preview report is a must-read for many in the pharma industry. Each year, we pull together some of our key pharma forecasts to build a picture of the future of this ever-changing market, from the biggest drugs and players, to the therapy areas in growth or decline. The report is excellent (not […]

The post In Case You Missed It: Three Things we Learned in our World Preview Webinar appeared first on Evaluate.

]]> https://www.evaluate.com/blog/3-things-we-learned-world-preview-webinar/feed/ 0 11443 The Processes Needed for Successful Pharmaceutical Forecasting https://www.evaluate.com/blog/the-processes-needed-for-successful-pharmaceutical-forecasting/ https://www.evaluate.com/blog/the-processes-needed-for-successful-pharmaceutical-forecasting/#respond Mon, 08 Jul 2024 16:29:36 +0000 https://www.evaluate.com/?p=11291 Many pharmaceutical companies are harnessing digital solutions to elevate global forecasting. Digital tools, such as cloud-based, SaaS environments, are powering efficient, streamlined, and intelligent forecasting processes. But, for technological solutions to empower pharma, there need to be robust forecasting processes in place to make them work in alignment with your business goals. Why are Forecasting […]

The post The Processes Needed for Successful Pharmaceutical Forecasting appeared first on Evaluate.

]]> https://www.evaluate.com/blog/the-processes-needed-for-successful-pharmaceutical-forecasting/feed/ 0 11291 Who’s winning in the battle for efficient capital deployment? https://www.evaluate.com/blog/efficient-capital-deployment/ https://www.evaluate.com/blog/efficient-capital-deployment/#respond Mon, 08 Jul 2024 13:32:20 +0000 https://www.evaluate.com/?p=11064 Over the last ten years, large pharma companies have spent an average of $120bn across R&D and business development investments. The net result? Portfolios worth approximately $210bn, according to Evaluate’s net present value (NPV) methodology. However, within these averages lie dramatically diverging performances, highlighting the challenges of deploying capital efficiently. Overall company performance is heavily […]

The post Who’s winning in the battle for efficient capital deployment? appeared first on Evaluate.

]]> https://www.evaluate.com/blog/efficient-capital-deployment/feed/ 0 11064 What’s Behind Pharma’s Growth Boost? https://www.evaluate.com/blog/whats-behind-pharmas-growth-boost/ https://www.evaluate.com/blog/whats-behind-pharmas-growth-boost/#respond Wed, 26 Jun 2024 16:30:30 +0000 https://www.evaluate.com/?p=10932 One of the milestones in the Evaluate year is the publication of our annual World Preview report, now in its 17th year. If you’re not familiar with the piece, it’s a deep dive into the state of the biopharma market, using Evaluate’s pharma forecasts to uncover key trends, challenges and drivers of growth (or indeed […]

The post What’s Behind Pharma’s Growth Boost? appeared first on Evaluate.

]]> https://www.evaluate.com/blog/whats-behind-pharmas-growth-boost/feed/ 0 10932 In Case You Missed It: Three Things we Learned in our Orphan Drugs Webinar https://www.evaluate.com/blog/in-case-you-missed-it-three-things-we-learned-in-our-orphan-drugs-webinar/ https://www.evaluate.com/blog/in-case-you-missed-it-three-things-we-learned-in-our-orphan-drugs-webinar/#respond Thu, 06 Jun 2024 17:00:15 +0000 https://www.evaluate.com/?p=10632 If you missed our recent webinar in which we dived in the orphan drugs landscape, you skipped a fascinating discussion between biopharma journalist Melanie Senior, author of our recent report “Have Orphans Lost Their Sparkle?”, Evaluate analyst Puru Gaur and special guest Stephanie Léouzon, Managing Director, Biopharma Healthcare at Stifel. The good news is that […]

The post In Case You Missed It: Three Things we Learned in our Orphan Drugs Webinar appeared first on Evaluate.

]]> https://www.evaluate.com/blog/in-case-you-missed-it-three-things-we-learned-in-our-orphan-drugs-webinar/feed/ 0 10632 The Future of Pharma Forecasting https://www.evaluate.com/blog/the-future-of-pharma-forecasting/ https://www.evaluate.com/blog/the-future-of-pharma-forecasting/#respond Sun, 02 Jun 2024 16:27:45 +0000 https://www.evaluate.com/?p=11196 What is FC365? In the fast-paced and ever-evolving world of pharmaceutical forecasting, having access to modern, high-performing tools is crucial. FC365 is addressing the industry’s unique needs, empowering forecasting teams to work more effectively and efficiently. Implementation of this SaaS platform across many leading pharma is now streamlining processes and bringing efficiencies. Saving teams valuable […]

The post The Future of Pharma Forecasting appeared first on Evaluate.

]]> https://www.evaluate.com/blog/the-future-of-pharma-forecasting/feed/ 0 11196 Neurology’s Renewal https://www.evaluate.com/blog/neurologys-renewal/ https://www.evaluate.com/blog/neurologys-renewal/#respond Thu, 23 May 2024 15:39:22 +0000 https://www.evaluate.com/?p=10411 In the realm of healthcare, neurology is experiencing a revival, marked by notable clinical advancements, increased deal activity, and a resurgence of interest from pharmaceutical giants. While perhaps not as widely discussed as topics like obesity, neuroscience’s return to the spotlight is evident through various indicators, including rising deal numbers and significant mergers and acquisitions. […]

The post Neurology’s Renewal appeared first on Evaluate.

]]> https://www.evaluate.com/blog/neurologys-renewal/feed/ 0 10411 Orphans are Getting Strategic https://www.evaluate.com/blog/orphans-are-getting-strategic/ https://www.evaluate.com/blog/orphans-are-getting-strategic/#respond Wed, 22 May 2024 15:17:09 +0000 https://www.evaluate.com/?p=10397 You may have read the new report we recently published on the orphan drug market. Rare diseases and their therapies are a huge topic to cover so inevitably, we couldn’t cover everything in the report. However, that’s what webinars are for! I’m delighted to be taking part in Evaluate’s upcoming webinar which will explore the […]

The post Orphans are Getting Strategic appeared first on Evaluate.

]]> https://www.evaluate.com/blog/orphans-are-getting-strategic/feed/ 0 10397 What’s the Deal? Navigating the Complex World of Pharma Business Development https://www.evaluate.com/blog/whats-the-deal-navigating-the-complex-world-of-pharma-business-development/ https://www.evaluate.com/blog/whats-the-deal-navigating-the-complex-world-of-pharma-business-development/#respond Tue, 07 May 2024 14:39:29 +0000 https://www.evaluate.com/?p=10053 2024 has the potential to be a year full of partnering opportunities, driven by the much-discussed patent cliff as some of the biggest-selling drugs in history are set to lose exclusivity by 2028. Perhaps as much as 6% of the nearly $1.6 trillion overall drug market might be at risk and while this isn’t Big […]

The post What’s the Deal? Navigating the Complex World of Pharma Business Development appeared first on Evaluate.

]]> https://www.evaluate.com/blog/whats-the-deal-navigating-the-complex-world-of-pharma-business-development/feed/ 0 10053 Meet the Team: Andrew Ward https://www.evaluate.com/blog/meet-the-evaluate-team-andrew-ward/ https://www.evaluate.com/blog/meet-the-evaluate-team-andrew-ward/#respond Tue, 30 Apr 2024 13:03:21 +0000 https://www.evaluate.com/?p=10017 If you missed the recent news, Evaluate recently acquired J+D Forecasting, a provider of brilliant forecasting solutions to pharma and biotech companies. Andrew Ward has been with the J+D team for almost 10 years as Head of Implementation team, ensuring that the team is able to meet the ever-evolving needs of their customers. I grabbed […]

The post Meet the Team: Andrew Ward appeared first on Evaluate.

]]> https://www.evaluate.com/blog/meet-the-evaluate-team-andrew-ward/feed/ 0 10017 Orphan Drug Report 2024: Slowdown a Sign of Success https://www.evaluate.com/blog/orphan-drug-report-2024-slowdown-a-sign-of-success/ https://www.evaluate.com/blog/orphan-drug-report-2024-slowdown-a-sign-of-success/#respond Wed, 24 Apr 2024 08:38:53 +0000 https://www.evaluate.com/?p=9569 Hot-off-the-press, Evaluate has just released its latest annual deep dive into the world of orphan drugs and rare diseases. I had the opportunity to preview the content and make the case for why it is essential biopharma reading below. And while I have your attention, you can grab your complimentary copy of Orphan Drug Report […]

The post Orphan Drug Report 2024: Slowdown a Sign of Success appeared first on Evaluate.

]]> https://www.evaluate.com/blog/orphan-drug-report-2024-slowdown-a-sign-of-success/feed/ 0 9569 US Health Systems: A Driving Force for Digital Health https://www.evaluate.com/blog/us-health-systems-a-driving-force-for-digital-health/ https://www.evaluate.com/blog/us-health-systems-a-driving-force-for-digital-health/#respond Tue, 09 Apr 2024 16:08:10 +0000 https://www.evaluate.com/?p=8590 The US Healthcare system is a vast, unwieldy beast that requires significant navigation by any company in the healthcare space. Whether you’re a Big Pharma, a small biotech or an innovative digital health developer, access to this market (and its payers) is likely to be make or break for your business. This, in a nutshell, […]

The post US Health Systems: A Driving Force for Digital Health appeared first on Evaluate.

]]> https://www.evaluate.com/blog/us-health-systems-a-driving-force-for-digital-health/feed/ 0 8590 Next Generation Dealmaking with Evaluate and Inpart https://www.evaluate.com/blog/next-generation-dealmaking-with-evaluate-and-inpart/ https://www.evaluate.com/blog/next-generation-dealmaking-with-evaluate-and-inpart/#respond Thu, 04 Apr 2024 18:50:29 +0000 https://www.evaluate.com/?p=8401 Dealmaking is a hallmark of the pharma industry. Whether to access innovative therapies, expand into new areas or fill a gap left from a failure in the clinic, pipelines need regular topping up to ensure companies can deliver long-term growth in the face of new competition, and loss of exclusivity. At Evaluate, we work closely […]

The post Next Generation Dealmaking with Evaluate and Inpart appeared first on Evaluate.

]]> https://www.evaluate.com/blog/next-generation-dealmaking-with-evaluate-and-inpart/feed/ 0 8401 Meet the Evaluate Team: Markella Kordoyanni https://www.evaluate.com/blog/meet-the-evaluate-team-markella-kordoyanni/ https://www.evaluate.com/blog/meet-the-evaluate-team-markella-kordoyanni/#respond Thu, 28 Mar 2024 18:10:31 +0000 https://www.evaluate.com/?p=7570 Markella is part of Evaluate’s competitive intelligence (CI) consulting practice, where she works on a wide range of projects to support CI teams in pharma companies to ensure they stay on top of the latest developments and are able to deliver timely insights to their stakeholders. I caught up with Markella to learn about what […]

The post Meet the Evaluate Team: Markella Kordoyanni appeared first on Evaluate.

]]> https://www.evaluate.com/blog/meet-the-evaluate-team-markella-kordoyanni/feed/ 0 7570 Competitive Intelligence Insights: Cell & Gene Therapy https://www.evaluate.com/blog/competitive-intelligence-insights-cell-gene-therapy/ https://www.evaluate.com/blog/competitive-intelligence-insights-cell-gene-therapy/#respond Wed, 27 Mar 2024 10:49:38 +0000 https://www.evaluate.com/?p=7436 The number of cell and gene therapy (C&GT)-based treatments in development has increased significantly over the last two decades and can be expected to continue, driven by the modality-specific market potential and the breadth of applicability across indications. For competitive intelligence teams tasked with staying on top of this complex and dynamic market, there is […]

The post Competitive Intelligence Insights: Cell & Gene Therapy appeared first on Evaluate.

]]> https://www.evaluate.com/blog/competitive-intelligence-insights-cell-gene-therapy/feed/ 0 7436 In Case You Missed It: Three Things We Learned in Our 2024 Preview Webinar https://www.evaluate.com/blog/in-case-you-missed-it-three-things-we-learned-in-our-2024-preview-webinar/ https://www.evaluate.com/blog/in-case-you-missed-it-three-things-we-learned-in-our-2024-preview-webinar/#respond Thu, 01 Feb 2024 12:10:52 +0000 https://www.evaluate.com/?p=5792 Our focus was on the 2024 Preview, our annual report that looks at the top drugs, companies, potential launches and much more for the year ahead. In the webinar, our team talked through some of the highlights and discussed some of the stories behind the data, with a view to what it means for pharma […]

The post In Case You Missed It: Three Things We Learned in Our 2024 Preview Webinar appeared first on Evaluate.

]]> https://www.evaluate.com/blog/in-case-you-missed-it-three-things-we-learned-in-our-2024-preview-webinar/feed/ 0 5792 Sneak Peek at Our 2024 Preview Webinar https://www.evaluate.com/blog/sneak-peek-at-our-2024-preview-webinar/ https://www.evaluate.com/blog/sneak-peek-at-our-2024-preview-webinar/#respond Mon, 29 Jan 2024 03:26:18 +0000 https://www.evaluate.com/?p=5759 Fortunately, the annual Preview report that we publish at Evaluate is based on our consensus forecasting data. While that doesn’t guarantee accuracy – in the current market, guarantees are hard to come by – it does mean that the insight we share is based on some pretty solid data. The 2024 Preview report was published […]

The post Sneak Peek at Our 2024 Preview Webinar appeared first on Evaluate.

]]> https://www.evaluate.com/blog/sneak-peek-at-our-2024-preview-webinar/feed/ 0 5759 Competitive Intelligence and the Quest for the Single Source of Truth https://www.evaluate.com/blog/competitive-intelligence-and-the-quest-for-the-single-source-of-truth/ https://www.evaluate.com/blog/competitive-intelligence-and-the-quest-for-the-single-source-of-truth/#respond Wed, 24 Jan 2024 03:48:24 +0000 https://www.evaluate.com/?p=5762 What’s in your competitor’s pipeline? How are their trials progressing? Who is on the cusp of a merger that will increase their funding and how will this impact your business? Continuous monitoring of the market landscape is the bread and butter of a CI professional and you can’t afford to miss anything that may impact […]

The post Competitive Intelligence and the Quest for the Single Source of Truth appeared first on Evaluate.

]]> https://www.evaluate.com/blog/competitive-intelligence-and-the-quest-for-the-single-source-of-truth/feed/ 0 5762 Knowledge and Insights: The Power of Real-World Data https://www.evaluate.com/blog/knowledge-insights-the-power-of-real-world-data/ https://www.evaluate.com/blog/knowledge-insights-the-power-of-real-world-data/#respond Tue, 23 Jan 2024 11:21:37 +0000 https://www.evaluate.com/?p=7441 Buzzwords in the life sciences industry – there are many: Artificial Intelligence (AI), Gen AI, Machine Learning (ML), digital health, and real-world data (RWD)/real world evidence (RWE). All are vast, complex areas with notable potential to impact our clients and the industry overall – across the continuum of the product lifecycle, spanning clinical and commercial […]

The post Knowledge and Insights: The Power of Real-World Data appeared first on Evaluate.

]]> https://www.evaluate.com/blog/knowledge-insights-the-power-of-real-world-data/feed/ 0 7441 2024 Preview: Are We There Yet? https://www.evaluate.com/blog/2024-preview-are-we-there-yet/ https://www.evaluate.com/blog/2024-preview-are-we-there-yet/#respond Wed, 17 Jan 2024 04:29:41 +0000 https://www.evaluate.com/?p=5770 After a year in which investor sentiment went from bad to worse, 2024 has started on a more positive note. Last week’s JP Morgan conference saw a flurry of partnership and acquisition announcements, building on the last couple of weeks of December which saw 2023’s deal making end with a bang. If the end is […]

The post 2024 Preview: Are We There Yet? appeared first on Evaluate.

]]> https://www.evaluate.com/blog/2024-preview-are-we-there-yet/feed/ 0 5770 In Case You Missed It: Three Things We Learned in Our CDMO Webinar https://www.evaluate.com/blog/in-case-you-missed-it-three-things-we-learned-in-our-cdmo-webinar/ https://www.evaluate.com/blog/in-case-you-missed-it-three-things-we-learned-in-our-cdmo-webinar/#respond Thu, 07 Dec 2023 11:25:50 +0000 https://www.evaluate.com/?p=5778 If you missed it, the recording is available here. If you’re short on time, here are three of the key points that I took away from the session. Our speakers included Amanda Micklus from the Norstella consulting team, and Vince Spurr, one of our CDMO experts. Perhaps more importantly, we were joined by Matt Hewitt […]

The post In Case You Missed It: Three Things We Learned in Our CDMO Webinar appeared first on Evaluate.

]]> https://www.evaluate.com/blog/in-case-you-missed-it-three-things-we-learned-in-our-cdmo-webinar/feed/ 0 5778 In Sickness and in Health: The CDMO/Pharma Relationship https://www.evaluate.com/blog/in-sickness-and-in-health-the-cdmo-pharma-relationship/ https://www.evaluate.com/blog/in-sickness-and-in-health-the-cdmo-pharma-relationship/#respond Tue, 28 Nov 2023 11:42:00 +0000 https://www.evaluate.com/?p=5782 There are two inflection points where a pharma or biotech company looks to a CDMO. In one instance, it’s a technology transfer to create regional or incremental capacity, helping reduce the risk of a single-source manufacturing process. While this isn’t risk-free, it’s relatively straightforward. In recent years, though, we’ve seen an increase in companies seeking […]

The post In Sickness and in Health: The CDMO/Pharma Relationship appeared first on Evaluate.

]]> https://www.evaluate.com/blog/in-sickness-and-in-health-the-cdmo-pharma-relationship/feed/ 0 5782 Themes from BIO Europe https://www.evaluate.com/blog/themes-from-bio-europe/ https://www.evaluate.com/blog/themes-from-bio-europe/#respond Fri, 17 Nov 2023 11:59:40 +0000 https://www.evaluate.com/?p=5787 There’s far too much to share in one blog post, but there were three areas that I wanted to summarise as I think they’re a good indicator of the current state of the biopharma market and give us an insight into what we can expect from pharma and biotech in 2024. 1. Dealmaking Increasing competition […]

The post Themes from BIO Europe appeared first on Evaluate.

]]> https://www.evaluate.com/blog/themes-from-bio-europe/feed/ 0 5787 Meet the Evaluate Team: Alex Bour https://www.evaluate.com/blog/meet-evaluate-team-alex-bour/ https://www.evaluate.com/blog/meet-evaluate-team-alex-bour/#respond Fri, 10 Nov 2023 07:57:06 +0000 https://www.evaluate.com/2023/11/30/meet-the-evaluate-team-alex-bour/ Alex Bour leads Evaluate’s Competitive Intelligence consulting practice, working closely with clients to help them to understand the nuances of their competitive environment and helping them to craft effective strategies. When you don’t find him knee-deep in Evaluate data, or pondering the latest in gene and cell therapy, you might discover him in the kitchen […]

The post Meet the Evaluate Team: Alex Bour appeared first on Evaluate.

]]> https://www.evaluate.com/blog/meet-evaluate-team-alex-bour/feed/ 0 4097 Quick View: Biopharma Dealmaking in Q3 https://www.evaluate.com/blog/quick-view-biopharma-dealmaking-in-q3/ https://www.evaluate.com/blog/quick-view-biopharma-dealmaking-in-q3/#respond Thu, 02 Nov 2023 07:57:07 +0000 https://www.evaluate.com/2023/11/30/quick-view-biopharma-dealmaking-in-q3/ The first half of the year showed some promise. Did the third quarter continue the trend? Well… If you read our round up of the state of the biopharma market at the halfway point of the year, you may have come away with, if not a spring in your step, then a least a little […]

The post Quick View: Biopharma Dealmaking in Q3 appeared first on Evaluate.

]]> https://www.evaluate.com/blog/quick-view-biopharma-dealmaking-in-q3/feed/ 0 4114 Meet the Evaluate Team: Jim Chuck https://www.evaluate.com/blog/meet-evaluate-team-jim-chuck/ https://www.evaluate.com/blog/meet-evaluate-team-jim-chuck/#respond Fri, 13 Oct 2023 07:57:06 +0000 https://www.evaluate.com/2023/11/30/meet-the-evaluate-team-jim-chuck/ Over four years into his Evaluate career, we thought it was time to find out a little more about Jim Chuck, one of our sales leaders who helps ensure that our clients find value in our solutions. He’s been working with and leading commercial functions for over 20 years and as well as being extremely […]

The post Meet the Evaluate Team: Jim Chuck appeared first on Evaluate.

]]> https://www.evaluate.com/blog/meet-evaluate-team-jim-chuck/feed/ 0 4101 CI Meets AI at Pharma CI https://www.evaluate.com/blog/ci-meets-ai-pharma-ci/ https://www.evaluate.com/blog/ci-meets-ai-pharma-ci/#respond Wed, 04 Oct 2023 07:57:04 +0000 https://www.evaluate.com/2023/11/30/ci-meets-ai-at-pharma-ci/ Last month saw many of the world’s leading pharma and biotech companies deploy their competitive intelligence (CI) specialists to Newark. Specifically, to the Pharma CI Conference and Exhibition that took place on 20th and 21st of September. I joined them, and it was one of the best iterations of the conference that I’ve been to […]

The post CI Meets AI at Pharma CI appeared first on Evaluate.

]]> https://www.evaluate.com/blog/ci-meets-ai-pharma-ci/feed/ 0 4074 In Case You Missed It: Three Things We Learned In Our World Preview Webinar https://www.evaluate.com/blog/case-you-missed-it-three-things-we-learned-our-world-preview-webinar/ https://www.evaluate.com/blog/case-you-missed-it-three-things-we-learned-our-world-preview-webinar/#respond Mon, 25 Sep 2023 07:57:06 +0000 https://www.evaluate.com/2023/11/30/in-case-you-missed-it-three-things-we-learned-in-our-world-preview-webinar/ You may have read the report, you may have pondered the infographic, but the best way to really get under the skin of the Evaluate World Preview report is to join the webinar. As well as sharing the highlights of the data from the report, the webinar gave our presenters a chance to really discuss […]

The post In Case You Missed It: Three Things We Learned In Our World Preview Webinar appeared first on Evaluate.

]]> https://www.evaluate.com/blog/case-you-missed-it-three-things-we-learned-our-world-preview-webinar/feed/ 0 4090 CDMO Focus: Three Areas to Drive Success https://www.evaluate.com/blog/cdmo-focus-three-areas-drive-success/ https://www.evaluate.com/blog/cdmo-focus-three-areas-drive-success/#respond Thu, 14 Sep 2023 07:57:04 +0000 https://www.evaluate.com/2023/11/30/cdmo-focus-three-areas-to-drive-success/ CDMOs (Contract Development and Manufacturing Organisations) are key players in the biopharma market, playing a vital role in translating science into medicines that change people’s lives. Almost all pharma and biotech companies rely on CDMO services to some extent, whether that’s for clinical trials or huge marketed drugs. However, CDMOs view the market through a […]

The post CDMO Focus: Three Areas to Drive Success appeared first on Evaluate.

]]> https://www.evaluate.com/blog/cdmo-focus-three-areas-drive-success/feed/ 0 4073 Latest Forecast: Lots to Discuss on Competitive Intelligence at Pharma CI https://www.evaluate.com/blog/latest-forecast-lots-discuss-competitive-intelligence-pharma-ci/ https://www.evaluate.com/blog/latest-forecast-lots-discuss-competitive-intelligence-pharma-ci/#respond Mon, 04 Sep 2023 07:57:06 +0000 https://www.evaluate.com/2023/11/30/latest-forecast-lots-to-discuss-on-competitive-intelligence-at-pharma-ci/ Somehow it is already September which means we’re preparing for one of the key events in the biopharma calendar, at least if you’re involved in competitive intelligence – and really, who isn’t? The Pharma CI Conference and Exhibition takes place in Newark on 20th and 21st of September and many of the Evaluate and Norstella […]

The post Latest Forecast: Lots to Discuss on Competitive Intelligence at Pharma CI appeared first on Evaluate.

]]> https://www.evaluate.com/blog/latest-forecast-lots-discuss-competitive-intelligence-pharma-ci/feed/ 0 4093 My Perfect Combination: Customers and Food https://www.evaluate.com/blog/my-perfect-combination-customers-and-food/ https://www.evaluate.com/blog/my-perfect-combination-customers-and-food/#respond Thu, 13 Jul 2023 07:57:07 +0000 https://www.evaluate.com/2023/11/30/my-perfect-combination-customers-and-food/ At the recent BIO International convention, I was able to combine two of my favourite things – talking to customers and an excellent meal!   Somehow, it’s already a month since BIO International. The week in Boston went by in a blur of meetings, conversations and networking but for me, there was one stand-out occasion. […]

The post My Perfect Combination: Customers and Food appeared first on Evaluate.

]]> https://www.evaluate.com/blog/my-perfect-combination-customers-and-food/feed/ 0 4106 Evaluate Omnium: An Award-Winning Decision https://www.evaluate.com/blog/evaluate-omnium-award-winning-decision/ https://www.evaluate.com/blog/evaluate-omnium-award-winning-decision/#respond Mon, 10 Jul 2023 07:57:04 +0000 https://www.evaluate.com/2023/11/30/evaluate-omnium-an-award-winning-decision/ Evaluate Omnium is now officially an award-winning solution!   Last month, we were delighted to announce that we have won an award. Evaluate Omnium, our machine learning-powered solution was named as Best Decision Management Solution by the AI Breakthrough awards. While we have always been very proud of Evaluate Omnium, and while we know that […]

The post Evaluate Omnium: An Award-Winning Decision appeared first on Evaluate.

]]> https://www.evaluate.com/blog/evaluate-omnium-award-winning-decision/feed/ 0 4079 BioSci Deal of the Month – Kite & Arcellx https://www.evaluate.com/blog/biosci-deal-month-kite-arcellx/ https://www.evaluate.com/blog/biosci-deal-month-kite-arcellx/#respond Wed, 28 Jun 2023 07:57:04 +0000 https://www.evaluate.com/2023/11/30/biosci-deal-of-the-month-kite-arcellx/ In December of 2022, Kite and Arcellx entered an agreement to develop and commercialise Arcellx’s multiple myeloma product candidate CART-ddBCMA. The candidate is currently in Phase 2 clinical development and is a cell therapy product comprising of genetically modified autologous T cells. The collaboration brings together Arcellx’s promising CART-ddBCMA therapy with Kite’s expertise and leadership […]

The post BioSci Deal of the Month – Kite & Arcellx appeared first on Evaluate.

]]> https://www.evaluate.com/blog/biosci-deal-month-kite-arcellx/feed/ 0 4069 Five Top Takeaways from BIO International 2023 https://www.evaluate.com/blog/five-top-takeaways-bio-international-2023/ https://www.evaluate.com/blog/five-top-takeaways-bio-international-2023/#respond Mon, 26 Jun 2023 07:57:06 +0000 https://www.evaluate.com/2023/11/30/five-top-takeaways-from-bio-international-2023/ A couple of weeks ago, we saw the return of BIO International to Boston for the first time since 2018. Since Boston is Evaluate’s home turf in the US, we headed to the gigantic Boston Convention Center to join 19,000 pharma, biotech and investment experts for four days of meetings, presentations, networking shindigs and sore […]

The post Five Top Takeaways from BIO International 2023 appeared first on Evaluate.

]]> https://www.evaluate.com/blog/five-top-takeaways-bio-international-2023/feed/ 0 4085 In Case You Missed It: Three Things We Learned In Our Gene Editing Webinar https://www.evaluate.com/blog/case-you-missed-it-three-things-we-learned-our-gene-editing-webinar/ https://www.evaluate.com/blog/case-you-missed-it-three-things-we-learned-our-gene-editing-webinar/#respond Thu, 15 Jun 2023 07:57:06 +0000 https://www.evaluate.com/2023/11/30/in-case-you-missed-it-three-things-we-learned-in-our-gene-editing-webinar/ Missed our gene editing webinar? Fear not! Here are a few of the highlights from our panel of experts which included Verve Therapeutics’ CEO, Sekar Kathiresan as well as our home-grown specialists. And if that’s not enough, the webinar is available on demand. Gene editing is a hot topic right now. With the first Pdufa […]

The post In Case You Missed It: Three Things We Learned In Our Gene Editing Webinar appeared first on Evaluate.

]]> https://www.evaluate.com/blog/case-you-missed-it-three-things-we-learned-our-gene-editing-webinar/feed/ 0 4089 Five Questions About the Future of Gene Editing https://www.evaluate.com/blog/five-questions-about-future-gene-editing/ https://www.evaluate.com/blog/five-questions-about-future-gene-editing/#respond Thu, 18 May 2023 07:57:04 +0000 https://www.evaluate.com/2023/11/30/five-questions-about-the-future-of-gene-editing/ Gene editing has been in and out of the news since Crispr hit the headlines a decade ago. It’s been anything from the next big thing to a borderline miracle to a potential menace. Is it just going through the same growing pains as any new technology in the pharma industry? Or is it fundamentally […]

The post Five Questions About the Future of Gene Editing appeared first on Evaluate.

]]> https://www.evaluate.com/blog/five-questions-about-future-gene-editing/feed/ 0 4082 BioSci Deal of the Month – Spero Therapeutics & GSK https://www.evaluate.com/blog/biosci-deal-month-spero-therapeutics-gsk/ https://www.evaluate.com/blog/biosci-deal-month-spero-therapeutics-gsk/#respond Mon, 15 May 2023 07:57:04 +0000 https://www.evaluate.com/2023/11/30/biosci-deal-of-the-month-spero-therapeutics-gsk/ In September of 2022, GSK and Spero Therapeutics entered into an exclusive license agreement for late-stage antibiotic asset, Tebipenem HBr. Tebipenem HBr is an oral carbapenem antibiotic aimed at treating complicated urinary tract infections including pyelonephritis. GSK will receive an exclusive license to develop and commercialise Tebipenem pivoxil and tebipenem pivoxil HBr in all territories […]

The post BioSci Deal of the Month – Spero Therapeutics & GSK appeared first on Evaluate.

]]> https://www.evaluate.com/blog/biosci-deal-month-spero-therapeutics-gsk/feed/ 0 4070 In Case You Missed It: Three Things We Learned From Our Orphan Drug Webinar https://www.evaluate.com/blog/in-case-you-missed-it-three-things-we-learned-from-our-orphan-drug-webinar/ https://www.evaluate.com/blog/in-case-you-missed-it-three-things-we-learned-from-our-orphan-drug-webinar/#respond Wed, 22 Mar 2023 07:57:06 +0000 https://www.evaluate.com/2023/11/30/in-case-you-missed-it-three-things-we-learned-from-our-orphan-drug-webinar/ Missed our webinar on orphan drugs and the impact of the Inflation Reduction Act? Well, you missed a lot but here are a few takeaways to help you catch up. And the full webinar is available on demand. Drugs for orphan indications are a fascinating area of the pharma industry. Our recent report on the […]

The post In Case You Missed It: Three Things We Learned From Our Orphan Drug Webinar appeared first on Evaluate.

]]> https://www.evaluate.com/blog/in-case-you-missed-it-three-things-we-learned-from-our-orphan-drug-webinar/feed/ 0 4087 BioSci Deal of the Month – Kainos Medicines & Emmaus Life Sciences https://www.evaluate.com/blog/biosci-deal-month-kainos-medicines-emmaus-life-sciences/ https://www.evaluate.com/blog/biosci-deal-month-kainos-medicines-emmaus-life-sciences/#respond Wed, 08 Mar 2023 07:57:04 +0000 https://www.evaluate.com/2023/11/30/biosci-deal-of-the-month-kainos-medicines-emmaus-life-sciences/ In February of 2021, Emmaus Life Sciences and Kainos Medicine entered into an agreement to jointly develop Kainos’ patented IRAK4 inhibitor (KM10544). IRAK4 is a serine-threonine protein kinase known to be present and active in the occurrence of certain immunity responses, inflammation disorders, and various cancers. Under the terms of this agreement, Kainos will study […]

The post BioSci Deal of the Month – Kainos Medicines & Emmaus Life Sciences appeared first on Evaluate.

]]> https://www.evaluate.com/blog/biosci-deal-month-kainos-medicines-emmaus-life-sciences/feed/ 0 4068 It’s All About Impact: Why Orphan Drugs are a Big Deal for Patients and Pipelines https://www.evaluate.com/blog/its-all-about-impact-why-orphan-drugs-are-big-deal-patients-and-pipelines/ https://www.evaluate.com/blog/its-all-about-impact-why-orphan-drugs-are-big-deal-patients-and-pipelines/#respond Mon, 27 Feb 2023 07:57:06 +0000 https://www.evaluate.com/2023/11/30/its-all-about-impact-why-orphan-drugs-are-a-big-deal-for-patients-and-pipelines/ 300 million people worldwide are living with a rare disease. The “orphan” drugs created to treat them have been a fast-growing part of the pharma market for years – and their use is often high profile. Every now and then a relative niche of the pharma world hits the mainstream – orphan drugs. It happened […]

The post It’s All About Impact: Why Orphan Drugs are a Big Deal for Patients and Pipelines appeared first on Evaluate.

]]> https://www.evaluate.com/blog/its-all-about-impact-why-orphan-drugs-are-big-deal-patients-and-pipelines/feed/ 0 4091